138 related articles for article (PubMed ID: 27905678)
1. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
Vormoor B; Veal GJ; Griffin MJ; Boddy AV; Irving J; Minto L; Case M; Banerji U; Swales KE; Tall JR; Moore AS; Toguchi M; Acton G; Dyer K; Schwab C; Harrison CJ; Grainger JD; Lancaster D; Kearns P; Hargrave D; Vormoor J
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27905678
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.
Moreno L; Marshall LV; Pearson AD; Morland B; Elliott M; Campbell-Hewson Q; Makin G; Halford SE; Acton G; Ross P; Kazmi-Stokes S; Lock V; Rodriguez A; Lyons JF; Boddy AV; Griffin MJ; Yule M; Hargrave D
Clin Cancer Res; 2015 Jan; 21(2):267-73. PubMed ID: 25370467
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
Hay AE; Murugesan A; DiPasquale AM; Kouroukis T; Sandhu I; Kukreti V; Bahlis NJ; Lategan J; Reece DE; Lyons JF; Sederias J; Xu H; Powers J; Seymour LK; Reiman T
Leuk Lymphoma; 2016; 57(6):1463-6. PubMed ID: 26376958
[No Abstract] [Full Text] [Related]
4. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Foran J; Ravandi F; Wierda W; Garcia-Manero G; Verstovsek S; Kadia T; Burger J; Yule M; Langford G; Lyons J; Ayrton J; Lock V; Borthakur G; Cortes J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):223-30. PubMed ID: 24355079
[TBL] [Abstract][Full Text] [Related]
5. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies.
Dent SF; Gelmon KA; Chi KN; Jonker DJ; Wainman N; Capier CA; Chen EX; Lyons JF; Seymour L
Invest New Drugs; 2013 Dec; 31(6):1522-9. PubMed ID: 24072436
[TBL] [Abstract][Full Text] [Related]
6. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Arkenau HT; Plummer R; Molife LR; Olmos D; Yap TA; Squires M; Lewis S; Lock V; Yule M; Lyons J; Calvert H; Judson I
Ann Oncol; 2012 May; 23(5):1307-1313. PubMed ID: 22015452
[TBL] [Abstract][Full Text] [Related]
7. A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.
Duong JK; Griffin MJ; Hargrave D; Vormoor J; Edwards D; Boddy AV
Br J Clin Pharmacol; 2017 Aug; 83(8):1713-1722. PubMed ID: 28177130
[TBL] [Abstract][Full Text] [Related]
8. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
Jayanthan A; Cooper TM; Hoeksema KA; Lotfi S; Woldum E; Lewis VA; Narendran A
Leuk Lymphoma; 2013 Jul; 54(7):1505-16. PubMed ID: 23176524
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
[TBL] [Abstract][Full Text] [Related]
10. AT9283 exhibits antiproliferative effect on tyrosine kinase inhibitor‑sensitive and ‑resistant chronic myeloid leukemia cells by inhibition of Aurora A and Aurora B.
Takeda T; Tsubaki M; Genno S; Nemoto C; Onishi Y; Yamamoto Y; Imano M; Satou T; Nishida S
Oncol Rep; 2020 Nov; 44(5):2211-2218. PubMed ID: 33000229
[TBL] [Abstract][Full Text] [Related]
11. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
12. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
Podesta JE; Sugar R; Squires M; Linardopoulos S; Pearson AD; Moore AS
Leuk Res; 2011 Sep; 35(9):1273-5. PubMed ID: 21665275
[TBL] [Abstract][Full Text] [Related]
13. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
14. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
[TBL] [Abstract][Full Text] [Related]
16. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.
Kimura S
Curr Opin Investig Drugs; 2010 Dec; 11(12):1442-9. PubMed ID: 21154126
[TBL] [Abstract][Full Text] [Related]
17. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.
Kantarjian HM; Schuster MW; Jain N; Advani A; Jabbour E; Gamelin E; Rasmussen E; Juan G; Anderson A; Chow VF; Friberg G; Vogl FD; Sekeres MA
Am J Hematol; 2017 Jul; 92(7):660-667. PubMed ID: 28370201
[TBL] [Abstract][Full Text] [Related]
19. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
[TBL] [Abstract][Full Text] [Related]
20. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
